Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection.
Journal
HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
02
2019
revised:
23
07
2019
accepted:
13
10
2019
pubmed:
18
11
2019
medline:
26
10
2021
entrez:
18
11
2019
Statut:
ppublish
Résumé
While resection is a recommended treatment for patients with stage 1 hepatocellular carcinoma (HCC), it remains controversial for multifocal disease. We sought to identify patients with multifocal HCC with survival after resection similar to patients with clinical stage 1 HCC. The National Cancer Database was queried to identify patients that underwent resection for HCC. In this study, 2990 patients with a single tumor, and 1087 patients with multifocal disease confined to one lobe underwent resection. In the multifocal cohort, patients with clinical stage 3 (HR 1.54, CI 1.31-1.81, p < 0.0001) or 4 (HR 2.27, CI 1.57-3.29, p < 0.0001) disease, and those with moderately-differentiated (HR 1.32, CI 1.06-1.64, p = 0.012) or poorly differentiated/undifferentiated tumors (HR 1.53, CI 1.20-1.95, p = 0.0006) were associated with worse overall survival (OS). There was no difference in OS between patients with well-differentiated clinical stage 2 multifocal HCC and those with all grades of clinical stage 1 HCC (median of 84.8 (CI 66.3-107.2) vs 76.2 months (CI 71.2-81.3), respectively, p = 0.356). Patients with well-differentiated, clinical stage 2 multifocal HCC confined to one lobe experience similar OS following hepatic resection to patients with clinical stage 1 disease. These findings may impact the management of select patients with multifocal HCC.
Sections du résumé
BACKGROUND
While resection is a recommended treatment for patients with stage 1 hepatocellular carcinoma (HCC), it remains controversial for multifocal disease. We sought to identify patients with multifocal HCC with survival after resection similar to patients with clinical stage 1 HCC.
METHODS
The National Cancer Database was queried to identify patients that underwent resection for HCC.
RESULTS
In this study, 2990 patients with a single tumor, and 1087 patients with multifocal disease confined to one lobe underwent resection. In the multifocal cohort, patients with clinical stage 3 (HR 1.54, CI 1.31-1.81, p < 0.0001) or 4 (HR 2.27, CI 1.57-3.29, p < 0.0001) disease, and those with moderately-differentiated (HR 1.32, CI 1.06-1.64, p = 0.012) or poorly differentiated/undifferentiated tumors (HR 1.53, CI 1.20-1.95, p = 0.0006) were associated with worse overall survival (OS). There was no difference in OS between patients with well-differentiated clinical stage 2 multifocal HCC and those with all grades of clinical stage 1 HCC (median of 84.8 (CI 66.3-107.2) vs 76.2 months (CI 71.2-81.3), respectively, p = 0.356).
CONCLUSIONS
Patients with well-differentiated, clinical stage 2 multifocal HCC confined to one lobe experience similar OS following hepatic resection to patients with clinical stage 1 disease. These findings may impact the management of select patients with multifocal HCC.
Identifiants
pubmed: 31734237
pii: S1365-182X(19)32273-7
doi: 10.1016/j.hpb.2019.10.1531
pmc: PMC7771330
mid: NIHMS1653874
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1004-1010Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Références
Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20
pubmed: 14762851
Hepat Oncol. 2018 May 10;5(1):HEP03
pubmed: 30302194
Surgery. 2013 Apr;153(4):510-7
pubmed: 23122930
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
HPB (Oxford). 2017 Oct;19(10):835-842
pubmed: 28734693
Hepatology. 2015 Aug;62(2):440-51
pubmed: 25678263
Saudi J Gastroenterol. 2015 Jan-Feb;21(1):11-7
pubmed: 25672233
J Hepatol. 2007 Nov;47(5):630-1
pubmed: 17881079
J Gastrointest Surg. 2015 Dec;19(12):2207-14
pubmed: 26394878
Cancer Control. 2017 Jul-Sep;24(3):1073274817729258
pubmed: 28975836
Hepatol Res. 2004 May;29(1):24-30
pubmed: 15135343
Ann Surg. 2009 May;249(5):799-805
pubmed: 19387322
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Hepatology. 2001 Jun;33(6):1394-403
pubmed: 11391528
Liver Transpl. 2018 Oct;24(10):1470-1475
pubmed: 30080954
World J Surg. 1997 Oct;21(8):860-4; discussion 864-5
pubmed: 9327679
J Magn Reson Imaging. 2017 May;45(5):1476-1484
pubmed: 27626270
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
World J Surg. 2000 Dec;24(12):1559-65
pubmed: 11193723
Ann Transl Med. 2015 Jan;3(1):4
pubmed: 25705636
Transl Gastroenterol Hepatol. 2017 Sep 27;2:78
pubmed: 29034351
Korean J Radiol. 2019 Apr;20(4):569-579
pubmed: 30887739
BMJ Open. 2012 Oct 22;2(5):
pubmed: 23089208
Front Med (Lausanne). 2017 Nov 10;4:193
pubmed: 29209611
Hepatology. 2017 Nov;66(5):1444-1453
pubmed: 28622419
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Oncologist. 2010;15 Suppl 4:34-41
pubmed: 21115579
Ann Surg. 2016 Oct;264(4):650-8
pubmed: 27433910
Radiographics. 2005 Oct;25 Suppl 1:S3-23
pubmed: 16227495